Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis

Massimo Filippi; Federica Agosta; Julian Grosskreutz; Michael Benatar; Jan Kassubek; Esther Verstraete; Martin R. Turner

doi:10.1016/S1474-4422(15)00134-9

Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis

Massimo Filippi^*, Federica Agosta, Julian Grosskreutz, Michael Benatar, Jan Kassubek, Esther Verstraete, Martin R. Turner

^*Korrespondierende/r Autor/-in für diese Arbeit

41 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	The Lancet Neurology
Jahrgang	14
Ausgabenummer	8
Seiten (von - bis)	786-788
Seitenumfang	3
ISSN	1474-4422
DOIs	https://doi.org/10.1016/S1474-4422(15)00134-9
Publikationsstatus	Veröffentlicht - 01.08.2015
Extern publiziert	Ja

Fördermittel

MF serves on scientific advisory boards for Teva Pharmaceutical Industries; has received compensation for consulting services and speaking activities from Biogen Idec, EXCEMED (Excellence in Medical Education), Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation, the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA). FA has received speaker's honoraria from Biogen Idec and EXCEMED, and receives research supports from the Italian Ministry of Health and AriSLA. EV has received compensation for consulting services as a member of the ALS Imaging Advisory Board for Biogen Idec. MRT has been a paid consultant to the Biogen Neuroimaging Advisory Panel. JG, MB, and JK declare no competing interests.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Zentren: Neuromuskuläres Zentrum Schleswig-Holstein

Dokumente

10.1016/S1474-4422(15)00134-9

Weitere Links

Link to publication in Scopus

Zitieren

@article{8c691b4ecdff4cf2bbbff3ff00c4bb5f,

title = "Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis",

author = "Massimo Filippi and Federica Agosta and Julian Grosskreutz and Michael Benatar and Jan Kassubek and Esther Verstraete and Turner, \{Martin R.\}",

note = "Funding Information: MF serves on scientific advisory boards for Teva Pharmaceutical Industries; has received compensation for consulting services and speaking activities from Biogen Idec, EXCEMED (Excellence in Medical Education), Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation, the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA). FA has received speaker's honoraria from Biogen Idec and EXCEMED, and receives research supports from the Italian Ministry of Health and AriSLA. EV has received compensation for consulting services as a member of the ALS Imaging Advisory Board for Biogen Idec. MRT has been a paid consultant to the Biogen Neuroimaging Advisory Panel. JG, MB, and JK declare no competing interests.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/S1474-4422(15)00134-9",

language = "English",

volume = "14",

pages = "786--788",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis

AU - Filippi, Massimo

AU - Agosta, Federica

AU - Grosskreutz, Julian

AU - Benatar, Michael

AU - Kassubek, Jan

AU - Verstraete, Esther

AU - Turner, Martin R.

N1 - Funding Information: MF serves on scientific advisory boards for Teva Pharmaceutical Industries; has received compensation for consulting services and speaking activities from Biogen Idec, EXCEMED (Excellence in Medical Education), Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation, the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA). FA has received speaker's honoraria from Biogen Idec and EXCEMED, and receives research supports from the Italian Ministry of Health and AriSLA. EV has received compensation for consulting services as a member of the ALS Imaging Advisory Board for Biogen Idec. MRT has been a paid consultant to the Biogen Neuroimaging Advisory Panel. JG, MB, and JK declare no competing interests.

PY - 2015/8/1

Y1 - 2015/8/1

UR - https://www.scopus.com/pages/publications/84937419358

U2 - 10.1016/S1474-4422(15)00134-9

DO - 10.1016/S1474-4422(15)00134-9

M3 - Comments/Debates

C2 - 26194923

AN - SCOPUS:84937419358

SN - 1474-4422

VL - 14

SP - 786

EP - 788

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 8

ER -